Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe COPD (AIRFLOW): A Multicenter Randomized Controlled Trial.

CONCLUSIONS: Patients with symptomatic COPD treated with TLD combined with optimal pharmacotherapy had fewer study defined respiratory adverse events, including hospitalizations for COPD exacerbation. Clinical trial registration available at clinicaltrials.gov, ID: NCT02058459. PMID: 31404499 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31404499?dopt=Abstract

Source: American Journal of Respiratory and Critical Care Medicine - August 11, 2019 Category: Respiratory Medicine Authors: Slebos DJ, Shah PL, Herth FJ, Pison C, Schumann C, Hübner RH, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Perez T, Skowasch D, Deslee G, Marceau A, Sciurba FC, Gosens R, Hartman JE, Srikanthan K, Duller M, Valipour A, AIRFLOW-2 Trial Study Tags: Am J Respir Crit Care Med Source Type: research